Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | GMNN | O75496 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.43 |
| ▸ | CCR6 | P51684 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28709594 | 0.93 | MEN1 (0.57) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL60120 | 0.91 | MEN1 (0.55) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL852481 | 0.82 | MEN1 (0.41) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL22653991 | 0.82 | MEN1 (0.41) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL5209281 | 0.81 | TSHR (0.33) | MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL2121174 | 0.79 | MEN1 (0.52) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL2171745 | 0.79 | TSHR (0.32) | MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL2121177 | 0.79 | MEN1 (0.52) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL9080744 | 0.78 | MEN1 (0.47) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL28237365 | 0.77 | MEN1 (0.55) | MEN1KMT2ACYP3A4PTGS1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931445-B2 | Composition comprising baicalin | L'OREAL (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-3558253-B1 | COMPOSITION COMPRISING BAICALIN | OREAL (FR) | 2022-12-28 | — | — | EP | disclosed |
| US-20200093724-A1 | COMPOSITION COMPRISING BAICALIN | L'OREAL (FR) | 2020-03-26 | — | — | US | disclosed |
| EP-3558253-A1 | COMPOSITION COMPRISING BAICALIN | L'Oreal (FR) | 2019-10-30 | — | — | EP | disclosed |
| EP-3525788-A1 | TREATMENT OF SYNUCLEINOPATHIES | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3493790-A1 | METHODS FOR THE PREPARATION OF LIPOSOMES | Curirx Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
| WO-2018115493-A1 | COMPOSITION COMPRISING BAICALIN | L'OREAL (FR) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115360-A1 | COMPOSITION COMPRISING BAICALIN, A FATTY ACID ESTER AND AN ALKYLPOLYGLYCOSIDE | L'OREAL (FR) | 2018-06-28 | — | — | WO | disclosed |
| WO-2012158844-A1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012085648-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2008133801-A1 | CERAMIDE DERIVATIVES AS MODULATORS OF IMMUNITY AND AUTOIMMUNITY | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1974013-A2 | IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | Anthrogenesis Corporation (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007079185-A2 | IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2005056524-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-06-23 | — | — | WO | disclosed |
| EP-1542991-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | Euro-Celtique, S.A. (LU) | 2005-06-22 | — | — | EP | disclosed |
| EP-1507528-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | Signal Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931445-B2 | Composition comprising baicalin | KRT18, S100A6, DSG1 | MEN1 1651/4885KMT2A 4129/4885CYP3A4 2421/4885 |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | MEN1 2375/4885KMT2A 2744/4885CYP3A4 3564/4885 |
| US-20200093724-A1 | COMPOSITION COMPRISING BAICALIN | KRT18, S100A6, DSG1 | MEN1 1651/4885KMT2A 4129/4885CYP3A4 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.